
Genitourinary
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 2023
FEATURING
Jacob Berchuck,
Atish Choudhury
- 855 views
- May 16, 2023
- 7
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU 2023
FEATURING
Alok Tewari
- 48 views
- May 16, 2023
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023
FEATURING
Wenxin Xu,
Toni Choueiri
- 241 views
- May 16, 2023
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023
FEATURING
Charlene Mantia,
Joaquim Bellmunt
- 119 views
- May 16, 2023
- 1
Dana-Farber Cancer Institute
Updates on the Management of Non-Clear Cell RCC
FEATURING
Bradley McGregor
- 183 views
- May 2, 2023
OncoAlert
RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clear-Cell RCC
FEATURING
Toni Choueiri
- 370 views
- March 1, 2023
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Prostate Cancer
FEATURING
Anthony D'Amico
- 117 views
- February 22, 2023
Dana-Farber Cancer Institute
CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis
FEATURING
Atish Choudhury
- 71 views
- July 28, 2022
Dana-Farber Cancer Institute
Current and Emerging Agents to Treat Advanced Bladder Cancer
FEATURING
Guru Sonpavde
- 812 views
- March 5, 2019
- 3
Dana-Farber Cancer Institute
DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)
FEATURING
Guru Sonpavde
- 356 views
- June 24, 2019
- 1